Releuko Injection, Solution
FDA Label NDC 70121-1569

55 label sections · Submitted to the FDA by Amneal Pharmaceuticals Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Releuko (NDC 70121-1569). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 patients with cancer receiving myelosuppressive chemotherapy, 1.2 patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, 1.3 patients with cancer undergoing bone marrow transplantation, 1.4 patients undergoing autologous peripheral blood progenitor cell collection and therapy, 1.5 patients with severe chronic neutropenia, 1.6 patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome), 2.1 dosage in patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for aml, 2.2 dosage in patients with cancer undergoing bone marrow transplantation, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.